Peringatan Keamanan

Carcinogenesis and animal reproduction studies have not been performed with calfactant. A single mutagenicity study produced a negative Ames assay. Overdose with calfactant has not yet been reported, but it is recommended that in the case of an overdose ventilation should be supported until all excess fluid is cleared from the lungs. Cyanosis, bradycardia and airway obstruction have been reported with administration of calfactant.

Calfactant

DB06415

small molecule approved

Deskripsi

Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C.

Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Half time clearance from the lung lumen was reported as 12 hours in a study of normal rabbits.
Volume Distribusi No human studies on the distribution of calfactant have been performed.
Klirens (Clearance) No human studies on the metabolism and elimination of calfactant have been performed.

Absorpsi

Calfactant is administered directly to the lung lumen surface where it acts. No human studies on absorption have been completed.

Metabolisme

Endogenous lung surfactant is produced and excreted by Type II alveolar pneumocytes to form a surface monolayer across the alveoli through adsorption. Through repeated contraction and expansion of an alveolus, this monolayer degrades and the surfactant is taken back up into the Type II alveolar pneumocyte for re-packaging. No human studies on the metabolism of calfactant have been completed, but it is likely metabolized through a similar mechanism to endogenous pulmonary surfactant.

Rute Eliminasi

No human studies on elimination of calfactant have been completed.

Interaksi Obat

141 Data
Ceritinib Calfactant may increase the bradycardic activities of Ceritinib.
Ivabradine Calfactant may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Calfactant.
Esmolol Esmolol may increase the bradycardic activities of Calfactant.
Betaxolol Betaxolol may increase the bradycardic activities of Calfactant.
Midodrine Midodrine may increase the bradycardic activities of Calfactant.
Pregabalin Pregabalin may increase the bradycardic activities of Calfactant.
Metoprolol Metoprolol may increase the bradycardic activities of Calfactant.
Isradipine Isradipine may increase the bradycardic activities of Calfactant.
Atenolol Atenolol may increase the bradycardic activities of Calfactant.
Diltiazem Diltiazem may increase the bradycardic activities of Calfactant.
Trimethadione Trimethadione may increase the bradycardic activities of Calfactant.
Timolol Timolol may increase the bradycardic activities of Calfactant.
Amlodipine Amlodipine may increase the bradycardic activities of Calfactant.
Digoxin Digoxin may increase the bradycardic activities of Calfactant.
Nimodipine Nimodipine may increase the bradycardic activities of Calfactant.
Nisoldipine Nisoldipine may increase the bradycardic activities of Calfactant.
Bendroflumethiazide Bendroflumethiazide may increase the bradycardic activities of Calfactant.
Sotalol Sotalol may increase the bradycardic activities of Calfactant.
Lercanidipine Lercanidipine may increase the bradycardic activities of Calfactant.
Lamotrigine Lamotrigine may increase the bradycardic activities of Calfactant.
Cinnarizine Cinnarizine may increase the bradycardic activities of Calfactant.
Propranolol Propranolol may increase the bradycardic activities of Calfactant.
Clonidine Clonidine may increase the bradycardic activities of Calfactant.
Ethosuximide Ethosuximide may increase the bradycardic activities of Calfactant.
Labetalol Labetalol may increase the bradycardic activities of Calfactant.
Bisoprolol Bisoprolol may increase the bradycardic activities of Calfactant.
Nicardipine Nicardipine may increase the bradycardic activities of Calfactant.
Dexmedetomidine Dexmedetomidine may increase the bradycardic activities of Calfactant.
Magnesium sulfate Magnesium sulfate may increase the bradycardic activities of Calfactant.
Verapamil Verapamil may increase the bradycardic activities of Calfactant.
Galantamine Galantamine may increase the bradycardic activities of Calfactant.
Tizanidine Tizanidine may increase the bradycardic activities of Calfactant.
Sufentanil Sufentanil may increase the bradycardic activities of Calfactant.
Alfentanil Alfentanil may increase the bradycardic activities of Calfactant.
Fentanyl Fentanyl may increase the bradycardic activities of Calfactant.
Levomenthol Levomenthol may increase the bradycardic activities of Calfactant.
Loperamide Loperamide may increase the bradycardic activities of Calfactant.
Donepezil Donepezil may increase the bradycardic activities of Calfactant.
Alprenolol Alprenolol may increase the bradycardic activities of Calfactant.
Remifentanil Remifentanil may increase the bradycardic activities of Calfactant.
Zonisamide Zonisamide may increase the bradycardic activities of Calfactant.
Pindolol Pindolol may increase the bradycardic activities of Calfactant.
Methyldopa Methyldopa may increase the bradycardic activities of Calfactant.
Rivastigmine Rivastigmine may increase the bradycardic activities of Calfactant.
Guanfacine Guanfacine may increase the bradycardic activities of Calfactant.
Felodipine Felodipine may increase the bradycardic activities of Calfactant.
Nitrendipine Nitrendipine may increase the bradycardic activities of Calfactant.
Perhexiline Perhexiline may increase the bradycardic activities of Calfactant.
Nifedipine Nifedipine may increase the bradycardic activities of Calfactant.
Amiodarone Amiodarone may increase the bradycardic activities of Calfactant.
Carvedilol Carvedilol may increase the bradycardic activities of Calfactant.
Bretylium Bretylium may increase the bradycardic activities of Calfactant.
Propafenone Propafenone may increase the bradycardic activities of Calfactant.
Acebutolol Acebutolol may increase the bradycardic activities of Calfactant.
Nadolol Nadolol may increase the bradycardic activities of Calfactant.
Bepridil Bepridil may increase the bradycardic activities of Calfactant.
Bevantolol Bevantolol may increase the bradycardic activities of Calfactant.
Practolol Practolol may increase the bradycardic activities of Calfactant.
Penbutolol Penbutolol may increase the bradycardic activities of Calfactant.
Mibefradil Mibefradil may increase the bradycardic activities of Calfactant.
Oxprenolol Oxprenolol may increase the bradycardic activities of Calfactant.
Nimesulide Nimesulide may increase the bradycardic activities of Calfactant.
Prenylamine Prenylamine may increase the bradycardic activities of Calfactant.
Cyclandelate Cyclandelate may increase the bradycardic activities of Calfactant.
Flunarizine Flunarizine may increase the bradycardic activities of Calfactant.
Fluspirilene Fluspirilene may increase the bradycardic activities of Calfactant.
Celiprolol Celiprolol may increase the bradycardic activities of Calfactant.
Dronedarone Dronedarone may increase the bradycardic activities of Calfactant.
Nebivolol Nebivolol may increase the bradycardic activities of Calfactant.
Lucinactant Lucinactant may increase the bradycardic activities of Calfactant.
Clevidipine Clevidipine may increase the bradycardic activities of Calfactant.
Methsuximide Methsuximide may increase the bradycardic activities of Calfactant.
Seletracetam Seletracetam may increase the bradycardic activities of Calfactant.
Nylidrin Nylidrin may increase the bradycardic activities of Calfactant.
Lacosamide The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Calfactant is combined with Lacosamide.
Dotarizine Calfactant may increase the bradycardic activities of Dotarizine.
Pasireotide Calfactant may increase the bradycardic activities of Pasireotide.
Nilvadipine Calfactant may increase the bradycardic activities of Nilvadipine.
Bufuralol Calfactant may increase the bradycardic activities of Bufuralol.
Beractant Calfactant may increase the bradycardic activities of Beractant.
Lanreotide Calfactant may increase the bradycardic activities of Lanreotide.
Tranilast Calfactant may increase the bradycardic activities of Tranilast.
Bopindolol Calfactant may increase the bradycardic activities of Bopindolol.
Bupranolol Calfactant may increase the bradycardic activities of Bupranolol.
Agmatine Calfactant may increase the bradycardic activities of Agmatine.
Crizotinib Crizotinib may increase the bradycardic activities of Calfactant.
Fingolimod Calfactant may increase the bradycardic activities of Fingolimod.
Tofacitinib Calfactant may increase the bradycardic activities of Tofacitinib.
Regorafenib Calfactant may increase the bradycardic activities of Regorafenib.
Indenolol Calfactant may increase the bradycardic activities of Indenolol.
Fendiline Calfactant may increase the bradycardic activities of Fendiline.
Eperisone Calfactant may increase the bradycardic activities of Eperisone.
Trimebutine Calfactant may increase the bradycardic activities of Trimebutine.
Pinaverium Calfactant may increase the bradycardic activities of Pinaverium.
Poractant alfa Calfactant may increase the bradycardic activities of Poractant alfa.
Arotinolol Calfactant may increase the bradycardic activities of Arotinolol.
Tolfenamic acid Calfactant may increase the bradycardic activities of Tolfenamic acid.
Barnidipine Calfactant may increase the bradycardic activities of Barnidipine.
Aranidipine Calfactant may increase the bradycardic activities of Aranidipine.

Referensi & Sumber

Synthesis reference: Notter RH, Wang Z, Egan EA, Holm BA: Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids. 2002 Jan;114(1):21-34. Pubmed(http://www.ncbi.nlm.nih.gov/pubmed/11841823).
Artikel (PubMed)
  • PMID: 11585026
    Willson D: Calfactant. Expert Opin Pharmacother. 2001 Sep;2(9):1479-93.
  • PMID: 16061594
    Bloom BT, Clark RH: Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics. 2005 Aug;116(2):392-9.
  • PMID: 15671432
    Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005 Jan 26;293(4):470-6.
  • PMID: 15201857
    Attar MA, Becker MA, Dechert RE, Donn SM: Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol. 2004 Oct;24(10):626-30.
  • PMID: 23300398
    Nguyen TN, Cunsolo SM, Gal P, Ransom JL: Infasurf and curosurf: theoretical and practical considerations with new surfactants. J Pediatr Pharmacol Ther. 2003 Apr;8(2):97-114. doi: 10.5863/1551-6776-8.2.97.
  • PMID: 9934915
    Willson DF, Zaritsky A, Bauman LA, Dockery K, James RL, Conrad D, Craft H, Novotny WE, Egan EA, Dalton H: Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network. Crit Care Med. 1999 Jan;27(1):188-95.
  • PMID: 19436610
    Logan JW, Moya FR: Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Ther Clin Risk Manag. 2009 Feb;5(1):251-60. Epub 2009 Mar 26.
  • PMID: 25855884
    Willson DF, Truwit JD, Conaway MR, Traul CS, Egan EE: The Adult Calfactant in Acute Respiratory Distress Syndrome Trial. Chest. 2015 Aug;148(2):356-64. doi: 10.1378/chest.14-1139.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Bles
    Suspension • - • Endotracheal • Canada • Approved
  • Infasurf
    Suspension • 35.7 mg/1mL • Endotracheal • US • Approved
  • Neosurf
    Suspension • - • Endotracheal • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul